DIAGNOS Provides a Market Update on Recent Trading

BROSSARD, Quebec, Feb. 14, 2018 (GLOBE NEWSWIRE) — DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we”) (TSX Venture:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), wishes to comment on recent trading by Dundee Corporation (“Dundee”).

On February 2nd, 2018, Dundee, through its wholly-owned subsidiary Dundee Resources Limited, disposed an aggregate of 2,026,000 common shares (“Shares”) of the Corporation on the TSX Venture Exchange. As stated in the February 8th, 2018 news release from Dundee, the Shares were initially acquired for investment purposes only. As an insider of DIAGNOS, in accordance with regulatory requirements, Dundee also filed an early warning report on SEDAR in respect of the trade. DIAGNOS was not made aware of the decision to dispose the Shares prior to the sale.

About DIAGNOS and its technologies
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging, text and traditional data mining.  DIAGNOS has developed its own Artificial Intelligence (“AI”) technologies, CARA and FLAIREFLAIRE is a powerful AI engine that provides the capability of analyzing large and complex data sets.  Using Deep Learning methodology combined with our own proprietary algorithms, we can deploy rapidly new solutions to the healthcare market.

Additional information on DIAGNOS is available at www.diagnos.ca and www.sedar.com.

For further information, please contact:             

Mr. André Larente, President Daniel Renaud or Thomas Renaud, Managing Directors
DIAGNOS Inc.  Arrowhead Business and Investment Decisions, LLC
Tel: 450-678-8882 ext. 224 Tel: +1 212 619 6889, ext. 7010
alarente@diagnos.ca diagnos@arrowheadbid.com


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Share this post